Decernotinib

Drug Profile

Decernotinib

Alternative Names: Adelatinib; VRT-831509; VX-509

Latest Information Update: 29 Jul 2015

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Vertex Pharmaceuticals
  • Class Amides; Aminopyridines; Anti-inflammatories; Antirheumatics; Pyrimidines; Pyrroles; Small molecules
  • Mechanism of Action Janus kinase 3 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Discontinued Rheumatoid arthritis

Most Recent Events

  • 24 Jun 2018 Biomarkers information updated
  • 01 Jul 2014 Vertex completes a phase IIb trial in Rheumatoid arthritis in USA, Argentina, Bulgaria, Czech Republic, Estonia, Germany, Hungary, Mexico, Poland, Romania, Russia, Serbia, Slovakia and Ukraine (NCT01590459) prior to July 2015
  • 01 Feb 2014 Vertex Pharmaceuticals completes a phase II trial in Rheumatoid arthritis in USA, South Africa, the Netherlands, Denmark, Lithuania & Estonia (NCT01754935)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top